3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Genitourinary
2
Gastrointestinal
1
Conditions
Prostatic Neoplasms
31
Testicular Neoplasms
4
Breast Neoplasms
4
Vomiting
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Testicular Germ Cell Tumor
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neuroblastoma
2
Neoplasms
2
Nausea
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Neutrophilic, Chronic
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
pembrolizumab
26
lenvatinib
7
belzutifan
5
Saline Solution
4
Docetaxel
4
epacadostat
3
enzalutamide
3
enfortumab vedotin
3
Surgical Procedures, Operative
3
Prednisone
3
Gemcitabine
3
Cisplatin
3
Paclitaxel
2
Dexamethasone
2
Calcium Dobesilate
2
vinflunine
1
pazopanib
1
olaparib
1
Sunitinib
1
Prednisolone
1
Oxaliplatin
1
Fluorouracil
1
Cystectomy
1
Carboplatin
1
Capecitabine
1
CB-1158
1
Bevacizumab
1
Axitinib
1
Albumin-Bound Paclitaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Dexamethasone
×
Genitourinary
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts